share_log

Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $7

Benzinga ·  May 8 14:18

Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and lowers the price target from $8 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment